Articles tagged with Lung Cancer
Researchers found that smoke triggers rapid changes in gene expression in the lungs of female mice, increasing expression of genes involved in estrogen metabolism. These findings suggest that estrogen metabolism may contribute to lung cancer in non-smoking women.
The Lung Cancer Research Foundation donated $25,000 to support TGen's lung cancer research, recognizing the institute's groundbreaking work in improving detection and treatment. This marks the second year of the 'Strides for Life' event, which aims to advance lung cancer research.
A phase III clinical trial found no significant difference in overall survival between AE-941 and placebo arms for patients with non-small cell lung cancer. The study suggests that shark cartilage-derived products do not support the treatment of lung cancer.
A large Phase III randomized trial of shark cartilage as a cancer agent found no survival benefit for patients with advanced non-small cell lung cancer. The study enrolled 379 newly-diagnosed patients and did not meet its primary endpoint: survival.
Complete Genomics sequenced a patient's lung tumor and normal tissue to detect somatic mutations and structural variations. The study found over 50,000 high-confidence single nucleotide variations, revealing an estimated genome-wide somatic mutation rate of 17.7 per Mb.
Peregrine's PS-targeting antibody bavituximab reactivates the immune system to attack and destroy cancer cells, potentially working synergistically with multiple therapies. The company plans to initiate two new Phase II trials in refractory and front-line lung cancer patients by mid-year.
Erlotinib maintenance therapy significantly improves progression-free and overall survival in patients with non-small-cell lung cancer. The treatment is generally well-tolerated, with mild to moderate side effects.
UT Southwestern Medical Center is part of a nationwide study offering free genetic testing for lung cancer patients. The study aims to identify mutations in malignant lung tumors and develop targeted therapies. Participants will have access to their test results and guidance on potential clinical trials.
A study published in the Journal of Thoracic Oncology found that high expression of CD24 is a negative independent prognostic factor for progression-free and cancer-specific survival in NSCLC. CD24-high expression was also associated with adenocarcinoma histology, higher risk of disease progression, and cancer-related death.
Researchers at Mayo Clinic are testing new endoscopic optics to detect precancerous polyps and micrometastasis. The pCLE system shows the highest accuracy yet in detecting small polyps, with a specificity of 100%. This technology has the potential to perform virtual biopsies, reducing unnecessary procedures.
Transplant patients have a significantly increased risk of developing lung cancer after organ transplantation, with the highest rates seen in heart and liver recipients. Researchers found that 0.85% of transplants developed lung cancer over 22 years, with higher incidence rates in smokers.
The European Society for Medical Oncology has approved a personalized treatment for lung cancer, based on tumor characteristics. This approach promises to improve patient outcomes and reduce toxicity compared to traditional treatments.
A new blood test has been found to identify patients with advanced non-small-cell lung cancer who are more likely to respond to erlotinib treatment. The test, which analyzes specific 'fingerprints' of a protein called EGFR, showed a significant response rate in patients with good proteomic profiles compared to those with poor profiles.
A Phase I trial combining pemetrexed with radiation and chemotherapy for stage III non-small-cell lung cancer demonstrates tolerability and efficacy. The regimen allows high cytotoxic doses during radiotherapy, increasing the chance of killing cancerous cells.
A new 4-dimensional software program helps doctors adjust for breathing movements when treating lung cancer with radiotherapy. This allows for more accurate targeting of tumors while minimizing damage to surrounding healthy tissues.
Analyzing Spanish gene expression data may help identify patients who will benefit most from treatment with angiogenesis-inhibitor drugs. Researchers found a correlation between high levels of VEGF-A and VEGFR-1 in tumor samples and poor prognosis, suggesting these genes could be used to tailor therapy to individual patients.
Researchers found that lung cancer patients whose tumors over-express the cell surface molecule CXCR4 have significantly worse clinical outcomes and shorter overall survival times. This suggests that CXCR4 could be a promising new target for personalized cancer therapy.
A study comparing lung cancer survival rates in England, Norway, and Sweden found that Swedes had the highest survival rates, with 16% of women diagnosed surviving five years. The difference in death rates was largely concentrated in the first year after diagnosis, suggesting a possible link between treatment activity and outcomes.
Almost 50% of AIDS patients died from AIDS, but non-AIDS related deaths increased after four years of treatment with ART. Lifestyle-related causes like suicide and liver disease were common non-AIDS deaths.
A NIST research team has found that using volumetrics can improve the accuracy of CT scans for diagnosing lung cancer, allowing physicians to notice smaller volume changes. This method could potentially cut diagnosis time from six months to four weeks.
Researchers found that metformin decreases insulin levels and inhibits tumor growth in mice exposed to tobacco carcinogens. Metformin reduced lung tumor burden by 40-72% in treated mice.
Researchers found that healthy older adults taking rosuvastatin had fewer heart problems and strokes than those not taking the medication. A high false-positive rate was associated with low-dose CT lung cancer screening, highlighting its potential harms. U.S. News rankings are criticized for relying too heavily on subjective data.
Researchers developed a novel statistical model to guide targeted therapies based on molecular signatures in tumor biopsies, showing promising results in treating stage IV non-small cell lung cancer. The study found that four drugs targeting specific molecular pathways led to improved disease control and overall survival.
A new Lancet editorial promotes the 'eat 5 fruit and veg a day' message despite recent findings suggesting a lower protective effect against cancer. Four key benefits remain: heart disease prevention, strong protection against specific cancers, weight management, and bowel cancer prevention.
Researchers have discovered a novel gene-expression-based approach to define oncogenic pathway signatures in the airway epithelium of smokers with lung cancer. This approach identifies specific genes belonging to the PI3K pathway, which are activated in high-risk smokers and may be reversed with a chemopreventive agent, myo-inositol.
A new study published in the Journal of Thoracic Oncology found that sleeve lobectomy offers superior survival and better postoperative pulmonary function compared to pneumonectomy in selected patients. The study analyzed 210 lung cancer patients and reported lower mortality rates for those who underwent a sleeve lobectomy.
Researchers at the University of Gothenburg have discovered two closely related enzymes, FT and GGT, as promising targets for treating lung cancer. By blocking these enzymes in transgenic mice, they found that cell growth was inhibited, tumour formation decreased, and survival rates improved.
A recent study found that genetic variations in the GPC5 gene are associated with an increased risk of lung cancer in never-smokers. The research, published in The Lancet Oncology, suggests that GPC5 could be a new target for drug development and could help identify high-risk individuals.
A recent study found that approximately 30% of never-smoking lung cancer patients carry a rare variant of the GPC5 gene, leading to reduced expression levels and increased risk of cancer. The research suggests that GPC5 may be a critical tumor suppressor gene in lung cancer development.
Studies reveal significant health disparities among Asian Americans, Native Hawaiians, and Pacific Islanders, with culturally appropriate care shown to reduce cancer rates and heart disease. Immigrant women face high risk of death from breast cancer, while obesity and high blood pressure are major concerns for Native Hawaiians.
Despite progress in cancer research, the disease remains a leading cause of death in the US. Advances in primary prevention, early detection, and treatment have improved outcomes for many cancers, but significant challenges remain, including the need for improved therapies.
Stereotactic body radiation therapy (SBRT) shows high rates of primary tumor control and improved survival for patients with inoperable non-small cell lung cancer. The study's findings suggest that SBRT provides more than double the rate of primary tumor control compared to conventional radiotherapy.
A phase II study found that stereotactic body radiation therapy (SBRT) effectively eliminated targeted tumors in patients with early-stage inoperable non-small cell lung cancer. The treatment resulted in a 97.6% primary tumor control rate at 3 years, outperforming conventional radiotherapy.
A review of gene expression-based prognostic signatures in lung cancer found little evidence to support their clinical application. The studies lacked statistical validation, reproducibility, and clear medical utility, highlighting serious problems with the design and analysis.
A genetic variant identified by researchers at the University of Cincinnati significantly increases lung cancer risk for individuals who smoke lightly, even if they are not heavy smokers. Family members with this genetic variant should be monitored for early detection, regardless of their smoking habits.
A new study suggests that stimulating human lung cancer cells with TLR7 or TLR8 agonists can lead to increased tumor cell survival and resistance to chemotherapy. This approach is being investigated as an adjuvant for anticancer immunotherapies, but caution should be exercised due to these potential risks.
Recent studies suggest that triggering TLR7 and TLR8 can actually increase tumor cell survival, while a new soluble factor IFN-beta represses tumor growth by limiting blood vessel formation. Additionally, microRNA-31 has been identified as an oncogenic factor promoting lung cancer through the repression of specific tumor suppressor genes.
Researchers found that lung cancer patients with optimistic attitudes had a six-month survival advantage over those with pessimistic attitudes. This study builds on existing research to investigate the effect of patient attitudes on outcomes in oncology populations.
Research found no significant differences in tolerance and efficacy between elderly and non-elderly NSCLC patients receiving salvage targeted therapy or chemotherapy. Elderly patients showed comparable response rates, disease control, and survival times as younger patients.
A new study published in the Journal of Clinical Oncology found that women taking estrogen plus progestin hormone replacement therapy for 10 or more years have a 50% increased risk of developing lung cancer compared to non-users. The study also suggests that duration of use is associated with an advanced stage of cancer at diagnosis.
Researchers found that African-Americans are more likely to hold fatalistic beliefs and be reluctant to seek medical attention for lung cancer symptoms. The study suggests that targeted public health messages are needed to address racial disparities in lung cancer treatment outcomes.
A new survey finds that African Americans are more likely to hold misconceptions about lung cancer, which could interfere with prevention and treatment. The study suggests that tailored public health messages are needed to address these disparities.
A large-scale study reveals over 100 genomic sites with missing or duplicated DNA in tumors, uncovering novel cancer genes and genetic abnormalities shared across multiple cancers. The study highlights the importance of common genomic alterations in driving cancer growth.
Research found that split-course palliative radiotherapy reduced patients' symptoms by 52-84% and provided long-lasting relief in 58% of cases. Cancer survival rates were not adversely affected by a two-week break in treatment, demonstrating the regimen's potential as an optimal option for symptom management.
The study found that molecular pathways involved in women's lung cancer are less complex than those in men, while elderly patients over 70 have a low-risk profile for long-term survival. The findings may help explain why certain groups of patients do better than others despite having the same disease.
A study of nearly 800 patients with non-small cell lung cancer identified genetic characteristics associated with increased recurrence-free survival, differing between men and women based on age.
A new approach to smoking cessation uses individualized risk assessments to motivate smokers to quit. Studies show that tests like Respiragene improve quit rates by providing smokers with personalized information about their risk of lung cancer and other smoking-related diseases.
Researchers have discovered that lung cancer tumors alter the odor of bodily fluids, allowing for early detection through trained animal sensors and chemical analysis. The findings hold promise for improving diagnostic and prognostic approaches to lung cancer treatment.
Scientists found that repeated exposure to tobacco smoke made lung cancer worse by causing inflammation in the lungs. The study provided definitive evidence for the role of lung inflammation in promoting lung cancer growth and suggested using anti-inflammatory agents to prevent or slow lung cancer progression.
Researchers identify a potential molecular mechanism by which NNK promotes lung tumor formation and development through DNMT1 accumulation. Accumulation of DNMT1 in lung adenomas from NNK-treated mice and tumors from lung cancer patients correlated with poor prognosis, suggesting an important link between tobacco smoking and lung cancer.
A team of researchers has identified a potential mechanism by which the tobacco-specific carcinogen NNK promotes lung tumor formation. They also found that statins may protect against invasive pneumococcal infections in children with sickle cell disease. Additionally, a new oncogenic protein called Nlp was discovered to be expressed at...
Researchers found that identifying patients with a small number of tumor cells harboring an overabundance of MET even before treatment can produce longer remissions when treated with combination drugs. This suggests that targeting these cells with additional drugs may be beneficial in preventing resistance.
A study published in BMC Public Health found that childhood traumas are associated with an increased risk of developing lung cancer. The researchers analyzed data from over 17,000 individuals and found that those who experienced six or more traumas were approximately three times more likely to develop lung cancer.
The American Association for Cancer Research and International Association for the Study of Lung Cancer honored Dr. Paul A. Bunn Jr., M.D., for his contributions to lung cancer research. The conference emphasized the importance of translational research in improving lung cancer prognosis.
A study found that erlotinib dosing in lung cancer patients depends on their smoking status, with smokers requiring lower doses than non-smokers. Non-smokers were able to tolerate higher doses without developing grade 2 or 3 toxicity, while smokers reached a maximum tolerated dose of 300mg daily.
A new study has found that patients with specific oncogenic rearrangements of the anaplastic lymphoma kinase (ALK) gene in their tumors respond significantly to an ALK-inhibitor therapy. The study suggests a paradigm shift in cancer drug development, allowing for more targeted treatments.
A new blood test has been developed to aid in lung cancer diagnosis and potentially reduce unnecessary invasive procedures. The test uses a 40-biomarker panel that correctly identified patients with lung cancer 88% of the time and those without it 79% of the time.
A recent study suggests that retreating patients with non-small cell lung cancer who initially responded to gefitinib treatment could lead to additional partial responses and stable disease. The overall disease control rate was 66.7 percent in the retreatment group, offering hope for patients who have failed initial chemotherapy.
A study found that drinking green tea could reduce the risk of lung cancer in smokers, particularly those with specific genetic profiles. Among smokers, those who drank at least one cup of green tea per day had a significantly lower risk of lung cancer compared to non-green tea drinkers.
A 93-gene signature associated with EGFR mutations in tumors from lung cancer patients was found to be a favorable prognostic marker for early stage lung cancer. The signature is also linked to drug sensitivity to erlotinib and gefitinib in non-small cell lung cancer cell lines.